囊性纤维化患者对BNT162b2新冠疫苗的体液与细胞免疫应答
研究纳入118例囊性纤维化(CF)患者和26名非CF受试者,在BNT162b2疫苗第2剂后约6-8个月至第3剂后8个月多个时间点检测抗体滴度和干扰素-γ释放,并随访突破感染至2022年10月。CF患者的细胞免疫应答与非CF受试者相似;低抗体滴度(<第1四分位数)与突破感染风险升高相关(HR 2.39,95%CI 1.17-4.88),低INF-γ水平(<0.3 IU/mL)无显著关联(HR 1.38,95%CI 0.64-2.99)。
要点
- CF患者接种BNT162b2后细胞免疫应答与非CF受试者相似。
- 低抗体滴度(<第1四分位数)与突破感染风险升高相关,HR 2.39(95%CI 1.17-4.88)。
- 低INF-γ水平(<0.3 IU/mL)与突破感染无显著关联,HR 1.38(95%CI 0.64-2.99)。
核心结论
- CF患者对BNT162b2疫苗的细胞免疫应答与非CF受试者相似;低抗体滴度与突破感染风险升高相关,而低INF-γ水平无显著关联。
研究设计与样本
- 研究纳入118例CF患者和26名非CF受试者,于2021年11月至2022年9月采样,随访突破感染至2022年10月。
- 在BNT162b2第2剂后约6-8个月至第3剂后8个月多个时间点检测体液(抗体滴度)和细胞免疫(干扰素-γ释放)应答。
主要发现
- CF患者产生的细胞免疫应答与非CF受试者相似。
- 低抗体滴度(<第1四分位数)与突破感染风险升高相关(HR 2.39,95%CI 1.17-4.88)。
- 低INF-γ水平(<0.3 IU/mL)与突破感染无显著关联(HR 1.38,95%CI 0.64-2.99)。
关键数值与推荐
- 低抗体滴度定义为<第1四分位数;低INF-γ水平定义为<0.3 IU/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需在接受免疫抑制治疗(如器官移植受者)的CF患者亚组中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
People with cystic fibrosis (pwCF) were considered to be clinically vulnerable to COVID-19 and were therefore given priority in the vaccination campaign. Vaccines induced a humoral response in these patients that was comparable to the response observed among the general population. However, the role of the cell-mediated immune response in providing long-term protection against SARS-CoV-2 in pwCF has not yet been defined. In this study, humoral (antibody titre) and cell-mediated immune responses (interferon-γ release) to the BNT162b2 vaccine were measured at different time points, from around 6-8 months after the 2nd dose and up to 8 months after the 3rd dose, in 118 CF patients and 26 non-CF subjects. Subjects were sampled between November 2021 and September 2022 and followed-up for breakthrough infection through October 2022. pwCF mounted a cell-mediated response that was similar to that observed in non-CF subjects. Low antibody titres (<1st quartile) were associated with a higher risk of breakthrough infection (HR: 2.39, 95 % CI: 1.17-4.88), while there was no significant association with low INF-γ levels (<0.3 IU/mL) (HR: 1.38, 95 % CI: 0.64-2.99). Further studies are needed in subgroup of pwCF receiving immunosuppressive therapy, such as organ transplant recipients. This data is important for tailoring vaccination strategies for this clinically vulnerable population.
引用
- Alicandro G, Orena BS, Rosazza C, et al. Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis. Vaccine. 2023. PMID: 37263872. doi:10.1016/j.vaccine.2023.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。